PPC
DYN icon

Park Place Capital’s Dyne Therapeutics DYN Stock Holding History

Park Place Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$852 Buy
+47
New +$810 ﹤0.01% 814

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Park Place Capital's DYN Position: Q1 2026 in Review

Park Place Capital opened a new position in Dyne Therapeutics (DYN) in Q1 2026: 47 shares worth $852. The stake represents ﹤0.01% of the portfolio and ranks #814 among its holdings.

227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Park Place Capital held 47 shares of Dyne Therapeutics worth $852 as of Q1 2026.
  • Dyne Therapeutics was a new Park Place Capital position in Q1 2026.
  • Dyne Therapeutics made up ﹤0.01% of Park Place Capital's portfolio in Q1 2026, its #814 holding.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.